Daiichi Sankyo Inks Discovery Deal With Next-Gen Protein Player Pieris
This article was originally published in PharmAsia News
Executive Summary
Privately-held Pieris AG announced April 12 a two-target partnership with Tokyo-based Daiichi Sankyo Co. Ltd. It is the German firm's latest alliance to center upon its proprietary anticalin platform and demonstrate its broad utility, which will be necessary if an acquisition is to transpire, although the company says it's not looking for an exit right now